Higher Dose of FLT190, Fabry Gene Therapy, To Be Tested Next

Higher Dose of FLT190, Fabry Gene Therapy, To Be Tested Next

322305

Higher Dose of FLT190, Fabry Gene Therapy, To Be Tested Next

The next patient to receive FLT190, an investigational gene therapy for Fabry disease, in the ongoing Phase 1/2 MARVEL-1 trial will be given a second, higher dose of therapy, accelerating an earlier trial timeline. This person was originally intended to be included in the first, lowest dose group of 7.5×1011  vector genomes per kilogram of body weight (vg/kg). But the trial instead is moving to a second dosing level of 1.5×1012 vg/kg, with a first patient…

You must be logged in to read/download the full post.